Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) dropped 3% on Tuesday . The company traded as low as $11.80 and last traded at $11.84. Approximately 40,221 shares traded hands during mid-day trading, a decline of 46% from the average daily volume of 74,921 shares. The stock had previously closed at $12.20.
Gyre Therapeutics Price Performance
The firm has a 50-day simple moving average of $12.83 and a 200-day simple moving average of $12.62.
Institutional Trading of Gyre Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after buying an additional 90,557 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company's stock valued at $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new stake in shares of Gyre Therapeutics in the third quarter worth about $334,000. WINTON GROUP Ltd bought a new position in Gyre Therapeutics during the second quarter valued at approximately $220,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $218,000. 23.99% of the stock is owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
(
Get Free Report)
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
Before you consider Gyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.
While Gyre Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
